Inactive Instrument

Governance Lannett Company, Inc.

LCI

US5160122009

Pharmaceuticals

Executive Committee: Lannett Company, Inc.

Manager

Positions heldSince

Timothy Crew

65 year

Chief Executive Officer

2017-12-31

Kristie Stephens

Chief Tech/Sci/R&D Officer	-
General Counsel	-

Samuel Israel

65 year

General Counsel

2017-07-16

Grant Brock

Chief Operating Officer

Composition of the Board of Directors: Lannett Company, Inc.

Director

CommitteesSince

Jeffrey Goldberg

60 year

Audit Committee	2023-11-30
Compensation Committee	2025-05-21
Governance Committee	2025-05-21
Nominating Committee	2025-05-21

James Bauersmith

Director/Board Member

Todd Clegg

Director/Board Member

Jason Shandell

52 year

Director/Board Member

2023-06-15

Timothy Crew

65 year

Director/Board Member

2017-12-31

Latest Appointments: Lannett Company, Inc.

23-06-16	Lannett Company, Inc. Emerges as a Private Company with New Board of Directors	CI
23-04-14	John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023	CI
23-04-14	John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023	CI
22-11-29	Jeffrey Farber Announces Not to Stand for the Re-Election to the Board of Lannett Company, Inc	CI
20-07-14	Lannett Company, Inc. Announces Executive Changes	CI
19-05-23	Lannett Company, Inc. Appoints Melissa V. Rewolinski to its Board of Directors, Effective July 1, 2019	CI
18-06-22	Lannett Company, Inc. Announces Termination of Kevin Smith as Senior Vice President of Sales, Effective June 30, 2018	CI

More news

Former Officers and Directors: Lannett Company, Inc.

Insider

Positions held

SinceUntil

Melissa Rewolinski

Director/Board Member	2019-06-30	2023-06-15
Independent Dir/Board Member	2019-06-30	2023-06-15

Pat LePore

Director/Board Member	2017-06-30	2018-06-30
Chairman	2018-06-30	2023-06-15
Independent Dir/Board Member	2017-06-30	2023-06-15

David Drabik

Director/Board Member	2010-12-31	2023-06-15
Independent Dir/Board Member	2010-12-31	2023-06-15

John Chapman

Director/Board Member	2018-06-30	2023-06-15
Independent Dir/Board Member	2018-06-30	2023-06-15

John Kozlowski

Comptroller/Controller/Auditor	2009-12-31	2018-04-21
Chief Operating Officer	2017-10-25	2018-04-21
Director of Finance/CFO	2019-08-30	2023-05-15
Human Resources Officer	2018-04-21	2019-08-30

Paul Taveira

Director/Board Member	2012-05-10	2022-01-25
Independent Dir/Board Member	2012-05-10	2022-01-25

Robert Ehlinger

Chief Tech/Sci/R&D Officer

2006-06-30

2021-11-30

G. Landis

Comptroller/Controller/Auditor	2009-03-31	2020-07-12
Corporate Officer/Principal	2009-03-31	-
Treasurer	-	2020-07-12

Albert Paonessa

Director/Board Member	2015-06-30	2020-01-21
Independent Dir/Board Member	2015-06-30	2020-01-21

Martin P. Galvan

Director/Board Member	2019-05-23	-
Director of Finance/CFO	2011-08-07	2019-08-29

James M. Maher

Director/Board Member	2013-06-30	2018-06-29
Independent Dir/Board Member	2013-06-30	2018-06-29

Kevin R. Smith

Sales & Marketing

2001-12-31

2018-06-29

Alicia Evolga

Sales & Marketing

2018-04-01

Arthur P. Bedrosian

Director/Board Member	2005-12-31	2018-01-01
Chief Executive Officer	2005-12-31	2018-01-01
Investor Relations Contact	2011-07-06	-
President	2002-04-30	2014-11-30

Kristin A. Arnold

Chief Tech/Sci/R&D Officer	2017-02-26	-
Corporate Officer/Principal	-	-

Mahendra Dedhiya

Chief Tech/Sci/R&D Officer	2015-05-31	-
Corporate Officer/Principal	2015-05-31	2016-10-20

Michael Bogda

Chief Operating Officer	2015-09-10	2016-06-02
President	2014-11-30	2016-06-02

William R. Farber

Director/Board Member	2011-07-26	2016-02-29
Chairman	1991-07-31	2011-07-26

William F. Schreck

Chief Operating Officer	2011-01-31	2015-09-10
Corporate Officer/Principal	2002-12-31	2011-01-31

Ernest J. Sabo

Compliance Officer	2005-02-28	2015-01-01
General Counsel	2005-02-28	2015-01-01

Myron D. Winkelman

Director/Board Member	2003-05-31	2012-12-30
Independent Dir/Board Member	2003-05-31	2012-12-30

Albert I. Wertheimer

Director/Board Member	2004-08-31	2012-12-30
Independent Dir/Board Member	2004-08-31	2012-12-30

Keith R. Ruck

Comptroller/Controller/Auditor	2010-01-03	2010-10-05
Director of Finance/CFO	2009-03-29	2011-07-31

Stephen J. Kovary

Chief Operating Officer	2010-01-03	2011-01-02
Corporate Officer/Principal	2009-09-13	2010-01-03

Bernard Sandiford

Chief Operating Officer

2002-10-31

2009-07-02

Brian J. Kearns

Director of Finance/CFO	2009-03-22	2009-03-22
Corporate Secretary	2009-03-22	2009-03-22
Treasurer	2009-03-22	2009-03-22

Andrew Uerkwitz

Comptroller/Controller/Auditor

2007-07-30

Kenneth Sinclair

Director/Board Member	2005-08-31	-
Independent Dir/Board Member	2005-08-31	-

Garnet Peck

Director/Board Member

2005-08-31

Karolos Gikas

Corporate Officer/Principal

2002-12-31

2003-12-31

Jeffrey Farber

Analyst-Fixed Income	2009-12-30	2009-12-30
Director/Board Member	2018-06-30	-
Chairman	2003-07-31	2018-06-30

Ronald A. West

Director/Board Member	2001-12-31	-
Chairman	2011-07-26	2012-07-16
Independent Dir/Board Member	2001-12-31	-

Ziv Leitman

Director of Finance/CFO

1985-12-31

1999-12-31

Alan Saidel

Chief Operating Officer

Vincent Cahill

Corporate Officer/Principal

Izak Shoshana

Corporate Officer/Principal

Igor Zhovnirovsky

Corporate Officer/Principal

Ronnie Pri Or

Sales & Marketing

Eyal Mayer

Corporate Officer/Principal

Avi A. Fogel

President

Larry Dalesandro

Director of Finance/CFO

Marvin Novick

Director/Board Member

David Farber

Corporate Officer/Principal

Bradley Rodos

Corporate Officer/Principal

2010-01-03

Age distribution of managers

Parity Men Women

Male	9
Female	2

Of which Executive Committee

Male	3
Female	1

Of which Directors

Male	5
Female	0

Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company's product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.

Employees

564

Sector

Pharmaceuticals

More about the company